(Q46465267)

22 December 2017

title

Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer (English)

1 reference

22 December 2017

Mucin 16, cell surface associated

1 reference

1 reference

1 reference

based on heuristic

inferred from title

author name string

Charlotte Hasselholt Søgaard

1

1 reference

22 December 2017

Jacob Chr Lindegaard

2

1 reference

22 December 2017

Hanne Havsteen

3

1 reference

22 December 2017

Ole Steen Nielsen

4

1 reference

22 December 2017

Ole Mogensen

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

22 December 2017

published in

Gynecologic Oncology

1 reference

22 December 2017

volume

97

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

410-412

1 reference

22 December 2017

CA 125 in the diagnosis of pelvic masses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Prognostic value of CA 125 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Serum CA 125 levels and survival in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Droloxifene-induced spikes of tumor markers predict benefit of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Predictive factors for long-term survival in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Prognostic indicators for poor risk epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Long-term results and prognostic factors in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.003

10.1016/J.YGYNO.2005.02.003

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017